

Venous thromboembolism prophylaxis in the trauma intensive care unit: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document

Joseph F Rappold,¹ Forest R Sheppard,¹ Samuel P Carmichael II ,² Joseph Cuschieri,³ Eric Ley,⁴ Erika Rangel,⁵ Anupamaa J Seshadri,⁶ Christopher P Michetti ⁷

¹Surgery, Maine Medical Center, Portland, Maine, USA

²Surgery, Wake Forest University, Winston-Salem, North Carolina, USA

³Surgery, University of Washington Seattle Campus, Seattle, Washington, USA

⁴Surgery, Cedars-Sinai Health System, Los Angeles, California, USA

⁵Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA

⁶Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

⁷Surgery, Inova Fairfax Hospital, Falls Church, Virginia, USA

Correspondence to

Dr Christopher P Michetti;
Christopher.Michetti@inova.org

Received 13 November 2020

Revised 27 January 2021

Accepted 6 February 2021

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite:

Rappold JF, Sheppard FR, Carmichael II SP, et al. *Trauma Surg Acute Care Open* 2021;**6**:e000643.

ABSTRACT

Venous thromboembolism (VTE) is a potential sequela of injury, surgery, and critical illness. Patients in the Trauma Intensive Care Unit are at risk for this condition, prompting daily discussions during patient care rounds and routine use of mechanical and/or pharmacologic prophylaxis measures. While VTE rightfully garners much attention in clinical patient care and in the medical literature, optimal strategies for VTE prevention are still evolving. Furthermore, trauma and surgical patients often have real or perceived contraindications to prophylaxis that affect the timing of preventive measures and the consistency with which they can be applied. In this Clinical Consensus Document, the American Association for the Surgery of Trauma Critical Care Committee addresses several practical clinical questions pertaining to specific or unique aspects of VTE prophylaxis in critically ill and injured patients.

INTRODUCTION

The American Association for the Surgery of Trauma (AAST) Critical Care Committee develops Clinical Consensus Document for critical care-related aspects of patient care. The goal of these documents is to provide practical answers to common clinical questions based on the best evidence available. They address focused topics for which the levels of evidence guiding care may not be strong and/or practice is controversial, and are based on expert consensus and review of the literature. Venous thromboembolism (VTE) prophylaxis, emphasizing the intensive care unit (ICU) environment, was chosen by the Committee as an area of practice warranting review and consensus.

Although enoxaparin has been the agent of choice for VTE prophylaxis in trauma patients since the seminal study by Geerts *et al* in 1996,^{1,2} two and a half decades later VTE remains a common complication for critically ill trauma and surgical patients.^{3–5} Increased and uninterrupted enoxaparin doses, guided by anti-Xa levels and/or weight, are considered safe and associated with lower VTE rates.^{6–10} Individual patient variables dictate when, how or if VTE prophylaxis is provided across the spectrum of traumatic injuries. Overall, the quality of published research on this topic is mixed with many studies

suffering from small numbers, heterogeneous populations, retrospective design, and potential bias.

This Clinical Consensus Document was created during the COVID-19 pandemic, a disease with its own unique risk of VTE, and for which elucidation of the pathophysiology and optimal management is still evolving as of this writing. Therefore, the Committee has opted to exclude discussion of COVID-related VTE from this work.

METHODS

The topic for this document was chosen through discussion by the AAST Critical Care Committee. A subgroup was formed comprising the document's authors. The subgroup formulated the clinical questions to be addressed and assigned research and writing tasks. The authors were tasked with researching their clinical questions through literature review and writing their section. Recommendations and content were then reviewed by the subgroup and revised based on feedback to achieve consensus. The subsequent draft was distributed to the Committee for review and comment prior to final editing by the first and last authors.

TRAUMATIC BRAIN INJURY

When should chemical VTE prophylaxis be initiated after TBI?

Recommendation

Thromboprophylaxis should be initiated as soon as possible following traumatic brain injury (TBI), balancing the risks of hemorrhagic expansion and VTE. The available literature supports initiation of prophylaxis 24–72 hours following admission, pending stability of intracranial/extra cranial hemorrhage and in conjunction with neurosurgical consultation.

Discussion

The incidence of VTE in trauma patients is highest during the first few days following hospitalization, and TBI confers its own elevated risk,¹¹ particularly when bleeding risk deters early administration of chemical prophylaxis. Among the TBI population, up to 54% may develop VTE in the absence of any form of prophylaxis and in 20%–30% of patients despite mechanical prophylaxis.^{12–13} Although recommendations for the optimal timing

of prophylaxis initiation have evolved over the past 10 years, the data remain heterogeneous with a paucity of randomized controlled trials due to the complex nature of the problem. Retrospective reviews conducted in 2011 demonstrated that, on average, prophylaxis was initiated following TBI on hospital days 3–4 after injury stability on repeat head CT. These studies included multiple forms of TBI and a range of Abbreviated Injury Scale (AIS) scores, but did not demonstrate any association between progression of intracranial hemorrhage (ICH) and timing of prophylaxis initiation. Although initiation within this time range did not significantly affect VTE incidence, correlations with VTE were observed in severe chest injury, lack of ambulation by discharge and interruptions in prophylaxis.^{12–15} In 2015, the American College of Surgeons Trauma Quality Improvement Project (TQIP) released guidelines on TBI management supporting consideration of VTE prophylaxis within the first 72 hours of hospitalization and following stable head CT.¹³ These guidelines incorporate the modified Berne-Norwood criteria in the strategic timing of prophylaxis initiation based on risk of ICH progression.¹⁶ In 2016, evaluation of the TQIP database used propensity score matching to optimize comparison of early (<72 hours) versus late (>72 hours) prophylaxis in severe TBI, showing lower rates of pulmonary embolus (PE) and deep vein thrombosis (DVT) in the early group without subsequent increases in neurosurgical intervention or mortality.² Most recently, Störmann *et al* presented findings from a single-center retrospective study in which patients with severe TBI were categorized into four groups by timing of prophylaxis initiation: <24 hours, 24–48 hours, >48 hours and no therapy. They showed that early (<24 hours) administration was not associated with ICH progression. While their overall incidence of ICH progression following prophylaxis (14.1%) is high versus historic comparison, it is less than that reported by Frisoli *et al* in a similar cohort (18%).^{17–18} The most recent guidelines from the Brain Trauma Foundation (BTF) concluded that there is insufficient evidence to support recommended timing of VTE prophylaxis initiation following TBI, underscoring the need for further high-quality investigation.¹⁹ More recently, a systematic review from 2020 evaluated 17 studies, and concluded that early chemoprophylaxis 24–72 hours after injury is associated with reduced VTE incidence without increasing ICH in patients with TBI with a stable repeat head CT.²⁰

Should severity of TBI influence timing and dosage of chemoprophylaxis?

Recommendation

Timing of prophylaxis initiation in TBI should be individualized and based on multiple factors, including injury severity.

Discussion

Severity of TBI is an incompletely understood factor in the timing of VTE prophylaxis, given the heterogeneity of head injury types. In surrogate, the Brain Injury Guidelines (BIG) and modified Berne-Norwood criteria provide guidance on classification of TBI and risk of ICH progression.^{16–21} Categorized as BIG 1–3, only patients meeting BIG 3 criteria (>8 mm ICH) required neurosurgical intervention. Furthermore, the Berne-Norwood criteria suggest that, in the absence of multiple contusions, for isolated subarachnoid/intraventricular hemorrhage and subdural/epidural ≤8 mm prophylaxis may safely be initiated at 24 hours postinjury pending stability of head CT. Additional stratification of TBI into moderate-risk and high-risk groups follows with a 72-hour delay in VTE prophylaxis initiation and consideration

of an inferior vena cava (IVC) filter, respectively. While unfractionated heparin (UFH) and the low molecular weight heparin (LMWH) enoxaparin are most commonly dosed at 5000 units every 8 hours and 30 mg every 12 hours, respectively, in TBI evaluation with the antifactor Xa assay allows for assessment of LMWH within a targeted range without increased risk of ICH progression.²²

Is there a preferred chemoprophylaxis agent for patients with TBI?

Recommendation

Either UFH or LMWH may be used for VTE prophylaxis in TBI, although LMWH may be superior.

Discussion

Optimal timing and type of prophylactic agent are critically important. Byrne *et al* recently evaluated the TQIP database for comparison of UFH versus LMWH in prevention of PE in major trauma.²³ Following propensity matching, LMWH was correlated with a significantly lower rate of PE versus UFH (1.4% vs 2.4%). This relationship was maintained in subgroup analysis of isolated severe TBI (AIS ≥3, Glasgow Coma Scale ≤8). Further review of TQIP by Benjamin *et al* reveals UFH to be independently predictive of mortality and VTE in severe TBI. Moreover, prophylaxis with LMWH did not increase the risk of unplanned emergency operation.²⁴ Although the use of UFH has decreased over time, its employment in TBI may be favored by some due to a theoretic benefit of shorter half-life. Additionally, database studies leave gaps in understanding regarding the types of head injuries being studied among other factors that may bias usage of one agent over the other. Current recommendations from the BTF support either UFH or LMWH for VTE prophylaxis and cannot conclusively endorse superiority of either, leaving room for future prospective studies.¹⁹ The use of LMWH offers some practical benefits over UFH, in that the lower number of injections may increase patient comfort and acceptance, decrease refusals and limit nurse-patient interactions (eg, for patients in isolation rooms). Emerging pharmacological VTE prophylaxis alternatives include the direct oral anticoagulants and aspirin, the latter of which is currently under investigation in a large randomized trial. Both options warrant further research but currently have insufficient evidence on which to formulate recommendations.

SOLID ORGAN INJURY

What timing and agent is appropriate for VTE prophylaxis after blunt solid organ injury?

Recommendation

In patients with blunt solid organ injury (SOI) undergoing non-operative management, VTE prophylaxis with LMWH should be initiated within 48 hours from time of injury in the absence of ongoing bleeding or other contraindications.

Discussion

Patients with blunt SOI, including liver, kidney and splenic injuries, are increasingly being managed non-operatively leading to questions as to when it is safe to initiate VTE prophylaxis in this population. For patients who have definitive hemostasis, prophylaxis should be initiated as soon as possible afterwards. However, in patients undergoing non-operative management, the concern for bleeding must be weighed against the risk of VTE. One retrospective study evaluating the thromboelastography (TEG) parameters of patients with blunt SOI demonstrated

conversion to a hypercoagulable state at 48 hours, suggesting that VTE prophylaxis is important by this time point.²⁵

While there has been no randomized trial comparing early and late initiation of VTE prophylaxis in SOI, there have been several observational studies comparing early (typically <48 hours after injury) with late (>48 hours after injury) initiation.^{26–32} Uniformly in these studies, there has been no increase in post-prophylaxis transfusion requirements or failure of non-operative management requiring intervention. Therefore, it appears that institution of VTE prophylaxis in patients with blunt SOI is safe and may be performed within 48 hours from the time of injury in the absence of ongoing bleeding. Of note, however, there is a paucity of data about outcomes in patients with grade IV–V injuries, likely because these injuries are more commonly managed operatively. Clinical judgment must be used in these higher grade injuries.

There are no high-quality data or consensus in the literature about the superiority of UFH or LMWH with regard to SOI specifically. However, LMWH is recommended in this population based on the cumulative evidence in favor of LMWH for multitrauma patients.

EPIDURAL ANALGESIA

Should trauma patients with epidural catheters receive pharmacological prophylaxis and, if so, which agent and at what dose?

Recommendation

Trauma patients with epidural catheters should receive enoxaparin at similar doses to those patients without catheters. In the presence of renal failure, UFH three times daily should be provided.

Discussion

Enoxaparin dosing is often interrupted after epidural catheter placement,⁷ leading to an increased VTE rate.³³ Regional anesthesia guidelines recommend a 12-hour interval between enoxaparin administration and placement or removal of an epidural catheter (24 hours if higher than standard dosing is used), and delaying resumption of the drug by 4–12 hours.^{34 35} Efforts to minimize the time without pharmacological protection should be undertaken by meticulously coordinating epidural procedures with drug doses, such that no more than two doses of enoxaparin will be missed. For UFH, the interval between epidural placement or removal and drug administration may be reduced to 4–6 hours, with only a 1-hour gap before resumption. As a result no UFH doses need be held.^{6 34 35}

IMAGING SURVEILLANCE FOR DVT

When is routine surveillance with venous duplex indicated after trauma?

Recommendation

Routine surveillance by venous duplex is not recommended for most trauma patients. Weekly surveillance may be performed in patients at high risk of VTE in whom chemical prophylaxis cannot be provided.

Discussion

Routine surveillance with venous duplex is not indicated or feasible for almost all trauma patients as it does not decrease the risk of VTE or fatal PE. In addition, false positive results

lead to unnecessary therapeutic anticoagulation.³⁶ Some centers advocate that routine surveillance in low-risk trauma patients will identify both acute and chronic DVT, which may help diagnose, treat or prevent the related complications such as venous insufficiency, venous stasis ulcers or pain with ambulation.³⁷ Alternatively, it is well known that increased imaging correlates with increased VTE rates,³⁸ with difficulty distinguishing clinically significant DVTs from incidental DVTs that would have remained clinically silent had they not been sought. Based on current evidence, routine surveillance duplex should be considered for trauma patients at high VTE risk who cannot be started or maintained on pharmacological prophylaxis, as this is associated with a reduced PE rate.³⁷

What is the appropriate strategy for diagnosis and prevention of VTE during and following venovenous extracorporeal membrane oxygenation?

Recommendation

Despite the use of systemic anticoagulation, venovenous (VV) extracorporeal membrane oxygenation (ECMO) is associated with a high rate of VTE that must be carefully evaluated and treated. Surveillance in patients who have undergone ECMO should use CT imaging to visualize deep veins and the IVC.

Discussion

While on VV ECMO, thrombotic events are provoked through interaction of the ECMO circuit and the patient's blood. To mitigate this risk, routine systemic anticoagulation and heparin-bonded circuits are used. However, anticoagulation may be held if significant bleeding occurs with the potential for exacerbating the inherent risk of VTE during VV ECMO. Although previous data during the H1N1 pandemic suggested the rate of VTE to be under 10%, recent data suggest this rate may be as high as 18%.³⁹ Thrombosis appears to occur more frequently with dual-lumen jugular cannulations compared with single lumen combined femoral cannulations. The sites of thrombosis are therefore more common in the internal jugular vein and IVC. Although the risk of VTE during VV ECMO may be related to both the duration of subtherapeutic anticoagulation and of the ECMO run,^{40–42} this has been disputed.⁴³

Following decannulation, DVT rates as high as 60% have been demonstrated and thus the routine use of venous duplex has been suggested at cannulation sites. Because of the inability to evaluate the iliac veins and vena cava through duplex, surveillance CT scan has been suggested as an adjunct. One study demonstrated the rate of overall cannula-associated thrombosis was 71% with 47% isolated to the vena cava.⁴⁴ This suggests that traditional duplex would miss a significant number of thromboses. In addition to DVT, 16% of patients were diagnosed with concurrent PE. The major modifiable factor associated with decannulation thrombosis was increased time of subtherapeutic anticoagulation. Although diagnosis is imperative, appropriate treatment should be initiated in patients with evidence of VTE. In patients without evidence of VTE, standard chemoprophylaxis should be initiated following decannulation.^{43–45}

PROPHYLACTIC INFERIOR VENA CAVA FILTERS

When should prophylactic inferior vena cava filters be used?

Recommendation

The use of prophylactic (in the absence of known VTE) inferior vena cava filters (IVCF) in trauma patients is controversial, but should be considered in very high-risk patients who cannot

receive chemical VTE prophylaxis for long periods because of increased bleeding risk.

Discussion

IVCF currently have indications in patients with known acute proximal (popliteal, femoral or iliac) DVT or PE who have an absolute contraindication to therapeutic anticoagulation; have suffered complications of anticoagulation or who have recurrent VTE while on adequate anticoagulation. The introduction of the retrievable IVCF in 2003 markedly increased insertion rates.^{46 47} Despite earlier evidence of a significant reduction in the incidence of PE following prophylactic IVCF in trauma patients,⁴⁸ more recent studies failed to show improvement in mortality⁴⁹ and report higher risk of DVT following insertion.⁵⁰ In the absence of level I evidence, conflicting professional guidelines regarding the use of IVCF in trauma patients have emerged.^{51–53} We suggest consideration of prophylactic IVCF only in the highest risk patients with contraindications to chemoprophylaxis due to an ongoing risk of life-threatening bleeding. Examples of such high-risk conditions include severe head injury plus long bone fractures, head injury plus spinal cord injury, multiple long bone fractures, severe pelvic fracture plus long bone fractures and/or medical conditions that predispose to bleeding.^{51 54}

How long should an IVCF remain in place?

Recommendation

It is essential that IVCFs be removed as soon as protection is no longer needed or when the patient can safely have chemoprophylaxis or therapeutic anticoagulation, to avoid long-term complications related to their presence. If a patient with an IVCF is later able to start anticoagulation, it should be initiated while the filter is still in place and the filter removed as soon as feasible. Multidisciplinary and systematic follow-up protocols should be established to optimize filter retrieval rates.

Discussion

Prolonged IVCF dwell times are associated with DVT, chronic pain, caval thrombosis, IVC perforation, filter migration and fracture.^{55 56} Retrieval success also decreases with duration of placement, with strut epithelialization and penetration through the caval wall making removal technically difficult.^{55 56} If the risk of PE has passed, prophylactic IVCF should be removed 1–2 months after implantation.⁵⁶ The American College of Chest Physicians recommends filters be removed 6 months following PE, regardless of the ability to anticoagulate the patient.⁵⁷ Despite the known complications of longer dwell times, most studies show retrieval rates remain lower than 50%.^{58–60} In response, the Food and Drug Administration issued an updated safety alert in 2014 recommending that implanting physicians accept responsibility for removal of filters as soon as clinically appropriate. A comprehensive follow-up program that tracks patients, assigns an individual dedicated to monitoring the program and educates physicians and patients is effective in minimizing loss to follow-up and improving retrieval rates.⁶¹

ANTIFACTOR XA MONITORING AND ASSOCIATED DOSE ADJUSTMENTS

What is the utility of antifactor Xa monitoring for VTE chemoprophylaxis?

Recommendation

A regimen for VTE prophylaxis using enoxaparin with dose adjustment based on anti-Xa levels may be considered for trauma and surgical ICU patients thought to have a low bleeding risk.

Such a regimen results in more patients having anti-Xa levels in the target range than with a fixed dosing regimen. However, evidence is insufficient to determine if this practice results in lower VTE rates. This strategy may not be appropriate for some patients (eg, those with TBI) and individual patient characteristics should be considered when choosing a dosing regimen.

Discussion

The study by Geerts *et al* in 1996¹ showed benefit of enoxaparin 30 mg twice a day in reducing venogram-diagnosed DVT rates, and minimal reduction with UFH (5000 units twice a day) in trauma. More recent evidence, mostly from underpowered retrospective studies, has suggested that the typical fixed dosing regimen of enoxaparin 30 mg two times per day does not inhibit factor Xa in a uniform and predictable manner in all patients.^{62–64} This makes intuitive sense, given the variable degree of VTE risk, hypercoagulability and sometimes unpredictable pharmacokinetics in critically ill and injured patients.

Anti-Xa activity is assessed via a functional assay that measures the degree of inhibition of factor Xa by UFH or LMWH. Blood for anti-Xa testing is typically drawn 4 hours after the third dose of enoxaparin. Levels are measured in International Units per milliliter, with target prophylactic levels falling in the range of 0.2–0.4 IU/mL (the target for therapeutic full anticoagulation is >0.5 IU/mL). If levels are below target, the dose may be increased by 10 mg and levels rechecked again 4 hours after the third new dose. Data on the maximum safe dose are insufficient, but several authors have recommended not exceeding 60 mg two times per day dosing. While true therapeutic dosing often exceeds 60 mg two times per day, the conditions under which clinicians may provide prophylactic enoxaparin may differ from those for therapeutic, especially when considering bleeding risk. Also, if anti-Xa levels have not reached prophylactic targets at higher doses, one should consider heparin resistance or anti-thrombin-III deficiency, occult VTE with high clot burden or other undetected factors that may prompt further investigation.

Studies supporting dose adjustments based on anti-Xa levels have suggested either that fixed dosing is insufficient to reach target anti-Xa levels,^{62–65} or that using a dose-adjustment regimen results in lower VTE rates.^{8 9} One larger retrospective study reported no decrease in VTE rates with an anti-Xa-based regimen⁶⁶; however, over half of study patients never achieved target levels during their hospital stay. Perhaps most relevant in this discussion is that the studies consistently report no increase in bleeding complications with anti-Xa-based dosing, which is a key concern in surgical ICU patients. Another possible use of anti-Xa monitoring is in patients with altered renal function. Since enoxaparin is cleared by the kidneys, renal dysfunction requires dose adjustment or discontinuation to avoid overanticoagulation due to drug retention. This is an area needing further study.

Given the low quality of the collective evidence, a broadly applicable recommendation cannot be made. A reasonable body of evidence supports the idea that standard enoxaparin dosing (30 mg two times per day) fails to raise anti-Xa levels to target, and that dose adjustment helps increase levels. However, many patients do not attain target anti-Xa levels despite incremental dose increases, and the relationship between drug dose and anti-Xa is not consistent between patients.

Anti-Xa-based regimens have not been well studied in patients with TBI, in whom bleeding complications can be catastrophic. Also, many studies on VTE prophylaxis are limited by missed doses of enoxaparin, which may alter drug efficacy and raise VTE risk.⁶⁷ The method of VTE diagnosis in studies is also

variable (routine screening vs symptom-prompted radiography), which is relevant since the clinical significance of small occult VTE is unknown.

VISCOELASTIC MONITORING AND DOSE ADJUSTMENT

What is the role of viscoelastic monitoring of VTE chemoprophylaxis?

Recommendation

Current evidence is inadequate to draw conclusions about the utility of TEG-guided enoxaparin dosing. Results from small studies in trauma and non-trauma patients have been mixed and inconclusive.

Discussion

TEG and rotational thromboelastometry are used frequently to provide a comprehensive assessment of coagulation status in trauma and surgical ICU patients. Many trauma patients become hypercoagulable after injury, as measured by TEG, which has been associated with higher VTE rates.^{68,69} Despite receiving presumably adequate pharmacological prophylaxis (enoxaparin 30 mg two times per day), VTE is still a major complication of severe injury. Dose adjustment of enoxaparin has been practiced based on weight and antifactor Xa levels but TEG has also been entertained as a monitoring method due to its ease of use and more complete assessment of coagulation. Although enoxaparin mainly inhibits factor Xa, it has minor effect on other elements of the clotting system and this makes TEG an attractive option for monitoring.⁷⁰

Few studies have examined TEG for VTE prophylaxis monitoring in trauma. A study of 61 trauma and general surgery patients with a 28% DVT rate showed that TEG distinguished those with and without DVT, while anti-Xa measurements did not.⁷¹ Patients with DVT had a shorter R-time (the TEG component measuring time to clot initiation). The same group examined TEG-guided versus standard enoxaparin dosing in a randomized trial of 87 patients,⁷² in which the dose was adjusted to achieve an R-time of 1–2 min. The median adjusted dose was 50 mg two times per day, with no difference in the change in R time between groups. Although the TEG-guided treatment led to increases in anti-Xa levels, this did not correlate with DVT rates. Interestingly, they also uncovered many patients with antithrombin-III deficiency, which the authors theorized may have accounted for the lack of change in R-time. In their follow-up study, the authors analyzed 89 patients and found that those with TEG-guided enoxaparin did not have a rise in anti-Xa levels until day 6, and that only about 12% of all patients achieved an increase in R-time over 1 min.⁷³

A study of 50 coronary care unit (CCU) patients receiving therapeutic dose enoxaparin⁷⁰ showed a positive association of TEG R-time and maximum rate of thrombin generation with enoxaparin dose, but no correlation of dosing with anti-factor Xa levels. Furthermore, TEG did not predict anti-Xa levels. Another study of 24 patients undergoing elective orthopedic surgery receiving prophylactic enoxaparin showed correlation of peak and trough anti-Xa activity with TEG R-time.⁷⁴

TEG remains worthy of investigation to determine its role in guiding pharmacological VTE prophylaxis. Currently, evidence is lacking to support its routine use in clinical patient care for this purpose.

WEIGHT-BASED DOSING OF ENOXAPARIN IN OBESITY

Should enoxaparin dosing be adjusted in patients with obesity?

Recommendation

Weight-based enoxaparin dosing for VTE prophylaxis is an acceptable strategy for trauma patients with body mass index (BMI)

>30 kg/m², based on earlier attainment of target anti-Xa levels and the significant prevalence of VTE in trauma patients receiving standard prophylaxis. Careful patient selection including assessment of both VTE and bleeding risk is warranted. Weight-based dosing is currently not recommended in patients with traumatic ICH.

Discussion

Obesity (defined as BMI >30 kg/m²) and traumatic injury are each associated with hypercoagulability and are well-known risk factors for VTE.^{75,76} VTE remains a common preventable complication in critically injured patients despite being a clinical focus of multiple national agencies⁷⁷ and the existence of best practice guidelines for prophylaxis.⁵¹ Patients with obesity have been under-represented in clinical trials of VTE prophylaxis, and recommendations for pharmacological prophylaxis in this population were not included in the American College of Chest Physicians 2012 guidelines.⁷⁸ Therefore, it is unclear if conventional prophylaxis measures are as effective in patients with obesity versus patients without obesity. Weight-based enoxaparin dosing has been used to attempt to improve efficacy of prophylaxis and reduce VTE rates in trauma patients with obesity. Although evidence for this strategy is still emerging, it is a common practice. In one multicenter study of trauma ICUs, 81.6% of 49 trauma centers reported using a weight-based dosing regimen.⁷⁹

Weight-based enoxaparin prophylaxis is commonly initiated at a dose of 0.5 mg/kg, 0.6 mg/kg or 30 mg for patients weighing 50–60 kg, 40 mg for patients weighing 61–99 kg and 50 mg for patients weighing >100 kg,¹⁰ in conjunction with measurement of anti-factor Xa levels toward a target range of 0.2–0.4 IU/mL. Small studies in trauma patients with obesity and non-trauma patients with obesity^{80–84} have demonstrated an advantage of the weight-based strategy in achieving target anti-Xa levels without an increased risk of bleeding. The predictable dosing relationship of enoxaparin among the LMWHs (1 mg enoxaparin inhibits 100 anti-Xa units) makes weight-based dosing based on anti-Xa measurements logical and convenient. A large retrospective study of hospital inpatients also reported a significant reduction in VTE rates in patients with morbid obesity (BMI >40 kg/m²) receiving higher dosing of enoxaparin and UFH compared with standard dosing.⁸⁵ Studies in bariatric surgery patients and other non-trauma populations have found no difference in bleeding complications with higher dosing.⁸⁵

Currently, weight-based enoxaparin dosing for VTE prophylaxis has a sound physiological rationale and support from low-quality studies in non-trauma patients. More investigation is needed in trauma patients with obesity, especially since these patients often have an elevated risk of VTE. While bleeding complications appear to be a rare event in non-trauma patients with a weight-based regimen, the nature of traumatic injury calls for careful patient selection when considering this practice in trauma ICU patients. Enoxaparin is renally cleared and therefore dose adjustment or use of UFH is necessary with acute or chronic kidney injury. It should be noted that there is a lack of evidence on the use of weight-based prophylaxis dosing in patients with traumatic ICH, unlike that which exists for standard dosing. Due to the unknown effect on progression of ICH with higher doses, at this time weight-based dosing is not recommended in this patient population.

OTHER HIGH-RISK SCENARIOS AND WHEN TO HOLD VTE PROPHYLAXIS

How should VTE prophylaxis be managed with active bleeding or coagulopathy?

Recommendation

Pharmacological prophylaxis should be delayed in patients with active bleeding or coagulopathy, until these conditions have

been controlled or reversed. Mechanical prophylaxis should be employed in these patients.

Discussion

It is appropriate to withhold chemical prophylaxis in patients with active bleeding or coagulopathy, or hemodynamic instability resulting from those conditions.⁶ Delaying initiation of enoxaparin should be minimized to the shortest acceptable time period, since the early trauma-induced coagulopathy soon gives way to a hypercoagulable state.^{25,86} In the setting of trauma coagulopathy, enoxaparin may be considered after completing the initial resuscitation, even though laboratory parameters of coagulation have not yet normalized.^{87,88} As holding pharmacological prophylaxis is associated with an increased VTE rate, enoxaparin initiation is encouraged if there are no signs of bleeding and the hypocoagulable state is expected to resolve.⁸⁷ Intermittent pneumatic compression as a means of mechanical prophylaxis is an important adjunct in conditions that prohibit chemical prophylaxis, especially in patients with moderate-to-high VTE risk.⁶

Should pharmacological VTE prophylaxis dosing be adjusted during pregnancy?

Recommendation

Dosing of pharmacological VTE prophylaxis should be adjusted in pregnant trauma patients.

Discussion

Pregnant trauma patients are at increased risk of VTE. Increases in weight and creatinine clearance make dosing adjustments for enoxaparin necessary, namely higher and more frequent dosing regimens. At admission, a pregnant trauma patient should receive enoxaparin 30 mg two times per day, and if the patient weighs >90 kg then 40 mg two times per day should be initiated. The dosing should then be titrated by antifactor Xa levels to target a range of 0.2–0.4 IU/mL.^{89,90}

When is it appropriate to hold doses of VTE chemoprophylaxis?

Recommendation

Once pharmacological prophylaxis is initiated, it should only be held or stopped for significant or potentially significant bleeding events and development of heparin-induced thrombocytopenia.

Discussion

The use of chemoprophylaxis is associated with a significant reduction in the risk of VTE. Initiation early during hospitalization in patients at high risk for the development of VTE is considered standard of care. However, initiation must be balanced with risk of bleeding, and as a result should be started when the risk of bleeding is acceptable. Once initiated, continuous therapy is essential. Interruption of VTE prophylaxis for a period of 24 hours and even missing a single dose is associated with an increased risk of VTE.⁷ As a result, chemoprophylaxis once initiated should be only held under unique circumstances. Despite this, interruption is common and up to 40% of patients have chemoprophylaxis held at some point or another. Interruptions due to surgery and procedures are an even more common reason for inconsistent chemoprophylaxis administration. Debate surrounds which operations and procedures are safe to continue chemoprophylaxis without interruption. Absolute indications for holding chemoprophylaxis include active hemorrhage and recent spine or intracranial surgery. However, the optimal timing of restarting chemoprophylaxis in

this patient population remains uncertain and ranges between 24 and 72 hours without clear data to guide decision making. Upcoming surgery or invasive procedures are considered relative indications for holding chemoprophylaxis. Outside of spine and intracranial surgery, little to no data exist demonstrating that continuing chemoprophylaxis without interruption leads to increased bleeding complications. In patients with a low risk of bleeding complications but high risk of VTE, chemoprophylaxis should be continued uninterrupted.^{77,91,92} If interruption in chemoprophylaxis is indicated, mechanical prophylaxis should be instituted prior to interruption and preferably continued in combination with re-initiation of pharmacological prophylaxis.

Contributors All authors contributed to the design, writing, and critical review of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement There are no data in this work.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Samuel P Carmichael II <http://orcid.org/0000-0003-0237-4244>

Christopher P Michetti <http://orcid.org/0000-0002-3744-0603>

REFERENCES

- Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. *N Engl J Med* 1996;335:701–7.
- Byrne JP, Mason SA, Gomez D, Hoefft C, Subacius H, Xiong W, Neal M, Pirouzmand F, Nathens AB. Timing of pharmacologic venous thromboembolism prophylaxis in severe traumatic brain injury: a Propensity-Matched cohort study. *J Am Coll Surg* 2016;223:621–31.
- Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH, Hernando C, Uribe M. Thromboprophylaxis for trauma patients. *Cochrane Database Syst Rev* 2013:CD008303.
- O'Donnell M, Weitz JI. Thromboprophylaxis in surgical patients. *Can J Surg* 2003;46:129–35.
- Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. *N Engl J Med* 1994;331:1601.
- Ley EJ, Brown CVR, Moore EE, Sava JA, Peck K, Ciesla DJ, Sperry JL, Rizzo AG, Rosen NG, Brasel KJ, et al. Updated guidelines to reduce venous thromboembolism in trauma patients: a Western trauma association critical decisions algorithm. *J Trauma Acute Care Surg* 2020;89:971–81.
- Louis SG, Sato M, Geraci T, Anderson R, Cho SD, Van PY, Barton JS, Riha GM, Underwood S, Differding J, et al. Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. *JAMA Surg* 2014;149:365–70.
- Ko A, Harada MY, Barmparas G, Chung K, Mason R, Yim DA, Dhillon N, Margulies DR, Gewertz BL, Ley EJ. Association between enoxaparin dosage adjusted by anti-factor Xa Trough level and clinically evident venous thromboembolism after trauma. *JAMA Surg* 2016;151:1006–13.
- Singer GA, Riggi G, Karcutskie CA, Vaghaiwalla TM, Lieberman HM, Ginzburg E, Namias N, Lineen EB. Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. *J Trauma Acute Care Surg* 2016;81:1101–8.
- Berndtson AE, Costantini TW, Lane J, Box K, Coimbra R. If some is good, more is better: an enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis. *J Trauma Acute Care Surg* 2016;81:1095–100.
- Denson K, Morgan D, Cunningham R, Niglicazzo A, Brackett D, Lane M, Smith B, Albrecht R. Incidence of venous thromboembolism in patients with traumatic brain injury. *Am J Surg* 2007;193:380–4.
- Koehler DM, Shipman J, Davidson MA, Guillaumondegui O. Is early venous thromboembolism prophylaxis safe in trauma patients with intracranial hemorrhage. *J Trauma* 2011;70:324–9.

- 13 American College of Surgeons. ACS TQIP best practices in the management of traumatic brain injury. Chicago. 2015. <https://www.facs.org/quality-programs/trauma/tqip/center-programs/tqip/best-practice> (12 Oct 2020).
- 14 Salottolo K, Offner P, Levy AS, Mains CW, Slone DS, Bar-Or D. Interrupted pharmacologic thromboprophylaxis increases venous thromboembolism in traumatic brain injury. *J Trauma* 2011;70:19–26.
- 15 Scudday T, Brasel K, Webb T, Codner P, Somberg L, Weigelt J, Herrmann D, Peppard W. Safety and efficacy of prophylactic anticoagulation in patients with traumatic brain injury. *J Am Coll Surg* 2011;213:148–53.
- 16 Pastorek RA, Cripps MW, Bernstein IH, Scott WW, Madden CJ, Rickert KL, Wolf SE, Phelan HA. The Parkland protocol's modified Berne-Norwood criteria predict two tiers of risk for traumatic brain injury progression. *J Neurotrauma* 2014;31:1737–43.
- 17 Störmann P, Osinloye W, Freiman TM, Seifert V, Marzi I, Lustenberger T. Early chemical thromboprophylaxis does not increase the risk of intracranial hematoma progression in patients with isolated severe traumatic brain injury. *World J Surg* 2019;43:2804–11.
- 18 Frisoli FA, Shinseki M, Nwabuobi L, Zeng XL, Adrados M, Kanter C, Frangos SG, Huang PP. Early venous thromboembolism chemoprophylaxis after traumatic intracranial hemorrhage. *Neurosurgery* 2017;81:1016–20.
- 19 Brain Trauma Foundation. Guidelines for the Management of Severe TBI, 4th Ed. <https://braintrauma.org/guidelines/guidelines-for-the-management-of-severe-tbi-4th-ed/#/> (21 Jun 2020).
- 20 Spano PJ, Shaikh S, Boneva D, Hai S, McKenney M, Elkbuli A. Anticoagulant chemoprophylaxis in patients with traumatic brain injuries: a systematic review. *J Trauma Acute Care Surg* 2020;88:454–60.
- 21 Joseph B, Friesse RS, Sadoun M, Aziz H, Kulvatunyou N, Pandit V, Wynne J, Tang A, O'Keefe T, Rhee P. The big (brain injury guidelines) project: defining the management of traumatic brain injury by acute care surgeons. *J Trauma Acute Care Surg* 2014;76:965–9.
- 22 Rodier S, Kim M, Moore S, Frangos S, Tandon M, Klein M, Berry CD, Huang PP, DiMaggio C, Bukur M. Early anti-Xa Assay-Guided low molecular weight heparin prophylaxis is safe in adult patients with acute traumatic brain injury. *J Am Coll Surg* 2019;229:5291–2.
- 23 Byrne JP, Geerts W, Mason SA, Gomez D, Hoefft C, Murphy R, Neal M, Nathens AB. Effectiveness of low-molecular-weight heparin versus unfractionated heparin to prevent pulmonary embolism following major trauma: a propensity-matched analysis. *J Trauma Acute Care Surg* 2017;82:252–62.
- 24 Benjamin E, Recinos G, Aiolfi A, Inaba K, Demetriades D. Pharmacological thromboembolic prophylaxis in traumatic brain injuries: low molecular weight heparin is superior to unfractionated heparin. *Ann Surg* 2017;266:463–9.
- 25 Chapman BC, Moore EE, Barnett C, Stovall RT, Biff WL, Burlew CC, Bensusan DD, Jurkovich GJ, Pieracci FM. Hypercoagulability following blunt solid abdominal organ injury: when to initiate anticoagulation. *Am J Surg* 2013;206:917–22.
- 26 Joseph B, Pandit V, Harrison C, Lubin D, Kulvatunyou N, Zangbar B, Tang A, O'Keefe T, Green DJ, Gries L, et al. Early thromboembolic prophylaxis in patients with blunt solid abdominal organ injuries undergoing nonoperative management: is it safe? *Am J Surg* 2015;209:194–8.
- 27 Skarupa D, Hanna K, Zeshan M, Madbak F, Hamidi M, Haddadin Z, Northcutt A, Gries L, Kulvatunyou N, Joseph B. Is early chemical thromboprophylaxis in patients with solid organ injury a solid decision? *J Trauma Acute Care Surg* 2019;87:1104–12.
- 28 Schellenberg M, Inaba K, Biswas S, Heindel P, Benjamin E, Strumwasser A, Matsushima K, Lam L, Demetriades D. When is it safe to start VTE prophylaxis after blunt solid organ injury? A prospective study from a level I trauma center. *World J Surg* 2019;43:2797–803.
- 29 Eberle BM, Schnüriger B, Inaba K, Cestero R, Kobayashi L, Barmparas G, Oliver M, Demetriades D. Thromboembolic prophylaxis with low-molecular-weight heparin in patients with blunt solid abdominal organ injuries undergoing nonoperative management: current practice and outcomes. *J Trauma* 2011;70:141–6.
- 30 Ferguson C, Lewin J. Bet 2: is early chemical thromboprophylaxis safe in patients with blunt trauma solid organ injury (SOI) undergoing non-operative management (nom)? *Emerg Med J* 2018;35:127–9.
- 31 Rostas JW, Manley J, Gonzalez RP, Brevard SB, Ahmed N, Frotan MA, Mitchell E, Simmons JD. The safety of low molecular-weight heparin after blunt liver and spleen injuries. *Am J Surg* 2015;210:31–4.
- 32 Khatsilouskaya T, Haltmeier T, Cathomas M, Eberle B, Candinas D, Schnüriger B. Thromboembolic prophylaxis with heparin in patients with blunt solid organ injuries undergoing non-operative treatment. *World J Surg* 2017;41:1193–200.
- 33 Vella MA, Dumas RP, Chreiman K, Wasser T, Smith BP, Reilly PM, Seamon MJ, Shiroff A. Epidural catheters are associated with an increased risk of venous thromboembolism in trauma. *J Thromb Thrombolysis* 2020;49:420–5.
- 34 Horlocker TT, Vandermeulen E, Kopp SL, Gogarten W, Leftert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of regional anesthesia and pain medicine evidence-based guidelines (fourth edition). *Reg Anesth Pain Med* 2018;43:263–9.
- 35 Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llaou JV, Samama CM, . European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. *Eur J Anaesthesiol* 2010;27:999–1015.
- 36 Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, Kearon C, Schunemann HJ, Crowther M, Pauker SG, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ED: American College of chest physicians evidence-based clinical practice guidelines. *Chest* 2012;141:e351S–418.
- 37 Allen CJ, Murray CR, Meizoso JP, Ginzburg E, Schulman CI, Lineen EB, Namias N, Proctor KG. Surveillance and early management of deep vein thrombosis decreases rate of pulmonary embolism in high-risk trauma patients. *J Am Coll Surg* 2016;222:65–72.
- 38 Bilimoria KY, Chung J, Ju MH, Haut ER, Bentrem DJ, Ko CY, Baker DW. Evaluation of surveillance bias and the validity of the venous thromboembolism quality measure. *JAMA* 2013;310:1482–9.
- 39 Zangrillo A, Biondi-Zoccai G, Landoni G, Frati G, Patroniti N, Pesenti A, Pappalardo F. ECMO in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 receiving ECMO. *Crit Care* 2013;17:R30.
- 40 Trudzinski FC, Minko P, Rapp D, Fährndrich S, Haake H, Haab M, Bohle RM, Flaig M, Kaestner F, Bals R, et al. Runtime and aPTT predict venous thrombosis and thromboembolism in patients on extracorporeal membrane oxygenation: a retrospective analysis. *Ann Intensive Care* 2016;6:66.
- 41 Camboni D, Philipp A, Lubnow M, Bein T, Haneya A, Diez C, Schmid C, Müller T. Support time-dependent outcome analysis for veno-venous extracorporeal membrane oxygenation. *Eur J Cardiothorac Surg* 2011;40:1341–6.
- 42 Cooper E, Burns J, Retter A, Salt G, Camporota L, Meadows CIS, Langrish CCJ, Wyncoll D, Glover G, Ioannou N, et al. Prevalence of venous thrombosis following venovenous extracorporeal membrane oxygenation in patients with severe respiratory failure. *Crit Care Med* 2015;43:581–4.
- 43 Menaker J, Tabatabai A, Rector R, Dolly K, Kufera J, Lee E, Kon Z, Sanchez P, Pham S, Herr DL, et al. Incidence of Cannula-Associated deep vein thrombosis after Venovenous extracorporeal membrane oxygenation. *Asaio J* 2017;63:588–91.
- 44 Parzy G, Daviet F, Persico N, Rambaud R, Scemama U, Adda M, Guervilly C, Hraiech S, Chaumoitre K, Roch A, et al. Prevalence and risk factors for thrombotic complications following venovenous extracorporeal membrane oxygenation: a CT scan study. *Crit Care Med* 2020;48:192–9.
- 45 Fisser C, Reichenbächer C, Müller T, Schneckenpointner R, Malfertheiner MV, Philipp A, Foltan M, Lunz D, Zeman F, Lubnow M. Incidence and risk factors for Cannula-Related venous thrombosis after venovenous extracorporeal membrane oxygenation in adult patients with acute respiratory failure. *Crit Care Med* 2019;47:e332–9.
- 46 Ho KM, Rao S, Honeybul S, Zellweger R, Wibrow B, Lipman J, Holley A, Kop A, Geelhoed E, Corcoran T, et al. A multicenter trial of vena cava filters in severely injured patients. *N Engl J Med* 2019;381:328–37.
- 47 Morales JP, Li X, Irony TZ, Ibrahim NG, Moynahan M, Cavanaugh KJ. Decision analysis of retrievable inferior vena cava filters in patients without pulmonary embolism. *J Vasc Med Biol* 2013;25:376–84.
- 48 Rogers FB, Shackford SR, Ricci MA, Wilson JT, Parsons S. Routine prophylactic vena cava filter insertion in severely injured trauma patients decreases the incidence of pulmonary embolism. *J Am Coll Surg* 1995;180:641–7.
- 49 Haut ER, Garcia LJ, Shihab HM, Brotman DJ, Stevens KA, Sharma R, Chelladurai Y, Akande TO, Shermock KM, Kebede S, et al. The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis. *JAMA Surg* 2014;149:194–202.
- 50 Hemmila MR, Osborne NH, Henke PK, Kepros JP, Patel SG, Cain-Nielsen AH, Birkmeyer NJ. Prophylactic inferior vena cava filter placement does not result in a survival benefit for trauma patients. *Ann Surg* 2015;262:577–85.
- 51 Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the East practice management guidelines work group. *J Trauma* 2002;53:142–64.
- 52 Cuschieri J, Freeman B, O'Keefe G, Harbrecht BG, Bankey P, Johnson JL, Minei JP, Sperry J, West M, Nathens A, et al. Inflammation and the host response to injury a large-scale collaborative project: patient-oriented research core standard operating procedure for clinical care X. guidelines for venous thromboembolism prophylaxis in the trauma patient. *J Trauma* 2008;65:944–50.
- 53 Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of chest physicians evidence-based clinical practice guidelines (8th edition). *Chest* 2008;133:381S–453S.
- 54 Winchell RJ, Hoyt DB, Walsh JC, Simons RK, Eastman AB. Risk factors associated with pulmonary embolism despite routine prophylaxis: implications for improved protection. *J Trauma* 1994;37:600–6.
- 55 Garcia-Godoy F, Collins T, Sacks D, Vasas S, Sarani B. Retrieval of inferior vena cava filters after prolonged indwelling time. *Arch Intern Med* 2011;171:1953–5.
- 56 Charlton-Ouw KM, Afaq S, Leake SS, Sandhu HK, Sola CN, Saqib NU, Azizadeh A, Safi HJ. Indications and outcomes of open inferior vena cava filter removal. *Ann Vasc Surg* 2018;46:205e5–11.
- 57 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of chest physicians evidence-based clinical practice guidelines (8th edition). *Chest* 2008;133:454S–545S.
- 58 Sarosiek S, Crowther M, Sloan JM. Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. *JAMA Intern Med* 2013;173:513–7.

- 59 Karmy-Jones R, Jurkovich GJ, Velmahos GC, Burdick T, Spaniolas K, Todd SR, McNally M, Jacoby RC, Link D, Janczyk RJ, et al. Practice patterns and outcomes of Retrievable vena cava filters in trauma patients: an AAST multicenter study. *J Trauma* 2007;62:17–25.
- 60 Johnson ON, Gillespie DL, Aidinian G, White PW, Adams E, Fox CJ. The use of Retrievable inferior vena cava filters in severely injured military trauma patients. *J Vasc Surg* 2009;49:410–6.
- 61 Goei AD, Josephs SC, Kinney TB, Ray CE, Sacks D. Improving the tracking and removal of Retrievable inferior vena cava filters. *Semin Intervent Radiol* 2011;28:118–27.
- 62 Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Baje M, Kong A, Lekawa ME, Dolich MO, Cinat ME, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. *J Trauma* 2010;68:874–80.
- 63 Rutherford EJ, Schooler WG, Sredzienski E, Abrams JE, Skeete DA. Optimal dose of enoxaparin in critically ill trauma and surgical patients. *J Trauma* 2005;58:1167–70.
- 64 Costantini TW, Min E, Box K, Tran V, Winfield RD, Fortlage D, Doucet J, Bansal V, Coimbra R. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. *J Trauma Acute Care Surg* 2013;74:128–33.
- 65 Walker CK, Sandmann EA, Horyna TJ, Gales MA. Increased enoxaparin dosing for venous thromboembolism prophylaxis in general trauma patients. *Ann Pharmacother* 2017;51:323–31.
- 66 Karcutskie CA, Dharmaraja A, Patel J, Eidelson SA, Padiadpu AB, Martin AG, Lama G, Lineen EB, Namias N, Schulman Cl, et al. Association of anti-factor Xa-Guided dosing of enoxaparin with venous thromboembolism after trauma. *JAMA Surg* 2018;153:144–9.
- 67 Patil S, Ayad M, Kaushal S, Gopal K, Patel B. Reducing the missed doses of VTE pharmacological prophylaxis is associated with reduction in VTE rate. *Chest* 2017;152:A460.
- 68 Brill JB, Badiee J, Zander AL, Wallace JD, Lewis PR, Sise MJ, Bansal V, Shackford SR. The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography. *J Trauma Acute Care Surg* 2017;83:413–9.
- 69 Gary JL, Schneider PS, Galpin M, Radwan Z, Munz JW, Achor TS, Prasarn ML, Cotton BA. Can thromboelastography predict venous thromboembolic events in patients with severe extremity trauma? *J Orthop Trauma* 2016;30:294–8.
- 70 White H, Sosnowski K, Bird R, Jones M, Solano C. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit. *Blood Coagul Fibrinolysis* 2012;23:304–10.
- 71 Van PY, Cho SD, Underwood SJ, Morris MS, Watters JM, Schreiber MA. Thromboelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. *J Trauma* 2009;66:1509–17.
- 72 Louis SG, Van PY, Riha GM, Barton JS, Kunio NR, Underwood SJ, Differding JA, Rick E, Ginzburg E, Schreiber MA. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial. *J Trauma Acute Care Surg* 2014;76:937–42.
- 73 Connelly CR, Van PY, Hart KD, Louis SG, Fair KA, Erickson AS, Rick EA, Simeon EC, Bulger EM, Arbabi S, et al. Thromboelastography-Based dosing of enoxaparin for thromboprophylaxis in trauma and surgical patients: a randomized clinical trial. *JAMA Surg* 2016;151:e162069.
- 74 Klein SM, Slaughter TF, Vail PT, Ginsberg B, El-Moalem HE, Alexander R, D'Ercole F, Greengrass RA, Perumal TT, Welsby I, et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. *Anesth Analg* 2000;91:1091–5.
- 75 Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis* 2016;41:3–14.
- 76 Kornblith LZ, Howard B, Kunitake R, Redick B, Nelson M, Cohen MJ, Callcut R. Obesity and clotting: body mass index independently contributes to hypercoagulability after injury. *J Trauma Acute Care Surg* 2015;78:30–6.
- 77 Lau BD, Streiff MB, Pronovost PJ, Haut ER. Venous thromboembolism quality measures fail to accurately measure quality. *Circulation* 2018;137:1278–84.
- 78 Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JJ, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ED: American College of chest physicians evidence-based clinical practice guidelines. *Chest* 2012;141:e227S–7S.
- 79 Michetti CP, Fakhry SM, Brasel K, Martin ND, Teicher EJ, Liu C, Newcomb A, . TRIPP Study Group. Structure and function of a trauma intensive care unit: a report from the trauma intensive care unit prevalence project. *J Trauma Acute Care Surg* 2019;86:783–90.
- 80 Bickford A, Majercik S, Bledsoe J, Smith K, Johnston R, Dickerson J, White T. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. *Am J Surg* 2013;206:847–51.
- 81 Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. *Thromb Res* 2010;125:220–3.
- 82 Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. *Am J Hematol* 2012;87:740–3.
- 83 Ludwig KP, Simons HJ, Mone M, Barton RG, Kimball EJ. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. *Ann Pharmacother* 2011;45:1356–62.
- 84 Wang T-F, Milligan PE, Wong CA, Deal EN, Thoeke MS, Gage BF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. *Thromb Haemost* 2014;111:88–93.
- 85 Shelkrot M, Miraka J, Perez ME. Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity. *Hosp Pharm* 2014;49:740–7.
- 86 Kornblith LZ, Moore HB, Cohen MJ. Trauma-induced coagulopathy: the past, present, and future. *J Thromb Haemost* 2019;17:852–62.
- 87 Sumislawski JJ, Kornblith LZ, Conroy AS, Callcut RA, Cohen MJ. Dynamic coagulability after injury: is delaying venous thromboembolism chemoprophylaxis worth the wait? *J Trauma Acute Care Surg* 2018;85:907–14.
- 88 Coleman JR, Kay AB, Moore EE, Moore HB, Gonzalez E, Majercik S, Cohen MJ, White T, Pieracci FM. It's sooner than you think: Blunt solid organ injury patients are already hypercoagulable upon hospital admission - Results of a bi-institutional, prospective study. *Am J Surg* 2019;218:1065–73.
- 89 Eubanks AA, Deering SH, Thiel LM. Risk assessment and treatment guide for obstetric thromboprophylaxis: comprehensive review of current guidelines. *Am J Perinatol* 2019;36:130–5.
- 90 Lamont MC, McDermott C, Thomson AJ, Greer IA. United Kingdom recommendations for obstetric venous thromboembolism prophylaxis: evidence and rationale. *Semin Perinatol* 2019;43:222–8.
- 91 Ramanathan R, Gu Z, Limkemann AJ, Chandrasekhar S, Rensing E, Mays C, Duane TM. Association between interruptions in chemical prophylaxis and VTE formation. *Am Surg* 2015;81:732–7.
- 92 Gao Y, Long A, Xie Z, Meng Y, Tan J, Lv H, Zhang L, Zhang L, Tang P. The compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery. *Springerplus* 2016;5:1362.